SCHEMBL25009183

SCHEMBL25009183

Cc1ccc(S(=O)(=O)c2nc(-c3ccc(F)cc3)oc2SC(C)C)cc1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.68
MAPT P10636 11/20 0.66
SMN1; SMN2 Q16637 5/20 0.66
ALDH1A1 P00352 4/20 0.66
POLB P06746 4/20 0.66
HSD17B10 Q99714 3/20 0.66
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
NPSR1 Q6W5P4 2/20 0.66
ALOX15 P16050 1/20 0.66
BLM P54132 1/20 0.66
TSHR P16473 3/20 0.66
HTT P42858 2/20 0.66
TP53 P04637 9/20 0.63
HPGD P15428 2/20 0.61
LMNA P02545 1/20 0.61
MAPK1 P28482 1/20 0.59
NPC1 O15118 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25010449 0.95 KDM4E (0.74) KDM4EMAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL25010442 0.90 MAPT (0.77) KDM4EMAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL25010084 0.90 KDM4E (0.67) KDM4EMAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL25009350 0.89 HSD17B10 (0.76) KDM4EMAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL25009622 0.89 MAPT (0.67) KDM4EMAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL25009171 0.88 MAPT (0.65) KDM4EMAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL25010436 0.87 KDM4E (0.90) KDM4EMAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL25009355 0.87 KDM4E (0.90) KDM4EMAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL25011037 0.85 TSHR (0.71) KDM4EMAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL25009620 0.84 TSHR (0.75) KDM4EMAPTSMN1; SMN2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230041576-A1 METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230041576-A1 METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY NFKBIA, IKBKB, NFKB2 KDM4E 2556/4885MAPT 2111/4885SMN1; SMN2 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.